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Introduction
Synovial tissues isolated from patients with rheumatoid
arthritis (RA) display biologic properties that differ from
‘normal’ synovium, and there is a rapidly expanding cata-
logue of biochemical and molecular changes that underlie
this phenotype [1]. We have investigated the feasibility of
using Moloney murine leukemia virus (MoMLV) based
vectors to constitutively express cloned genes in primary
human fibroblast-like synovial cells (FLS), with the long-
term objective of defining the contributions of specific sig-
naling pathways and inflammatory mediators to the
destructive phenotype of FLS in RA.
Prior studies have suggested that MoMLV-based vectors
transduced FLS with relatively low efficiency [2–5]. We
designed experiments to determine if viral titer influenced
FLS transduction by concentration of retrovirus. In these
experiments, we used a modified MoMLV vector (pRET2),
designed to improve transcriptional stability in primary
cells. We also employed the enhanced green fluorescent
protein (EGFP) as a virally encoded transgene to optimize
a rapid and efficient superspeed centrifugation technique
for concentration of viral supernatant. Viral particles were
concentrated to >108 colony forming units (cfu)/ml by
superspeed centrifugation at 20,000 g for four hours. Up
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to 50% of primary human FLS were transduced in vitro fol-
lowing a single exposure to concentrated viral supernatant.
Materials and methods
Cell Culture
Murine fibroblast NIH 3T3 cells, amphotropic PA317
packaging cells, and Phoenix E ecotropic packaging cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM)-high glucose (GIBCO-BRL, Grand island, NY,
USA) supplemented with 10% heat-inactivated fetal
bovine serum (GIBCO-BRL, Grand island, NY, USA),
100 U/ml penicillin, 100 µg/ml streptomycin, and 200 mM
L-glutamine. The FLS cultures were established from syn-
ovial tissues obtained during joint replacement surgery in
RA patients [6]. The FLS were cultured in DMEM plus
10% heat-inactivated human AB serum (BioWhittaker,
Walkersville, MD, USA), 10% fetal bovine serum, peni-
cillin, streptomycin, and L-glutamine. The FLS were used
between the third and tenth passage.
Construction of retroviral vector and producer cells
The EGFP cDNA was PCR amplified from pEGFP-1
(Clontech, Palo Alto, CA, USA) and subcloned into
pRET2, a modified version of the MoMLV-based MFG
retroviral vector, designed to optimize gene expression in
primary cell lines. The pRET2 incorporates long-terminal
repeats from the myeloproliferative sarcoma virus [7], and
a point mutation in the primer binding site [8]. A vector
expressing the human cyclooxygenase-2 (COX-2) cDNA
was constructed in the same backbone (pRET2.COX2).
Amphotropic viral producers were established in PA317
cells (see Supplementary Material).
Concentration of viral supernatant by superspeed
centrifugation
Fresh medium was added to subconfluent producer cell
monolayers, collected 24 hours later, and filtered
(0.45 µM) prior to use. Centrifugation was performed at
4°C in a Sorval RC-5B centrifuge, using SS-34 or GSA
rotors. Following centrifugation, the supernatant was aspi-
rated and saved for analysis. The viral pellet was resus-
pended in fresh medium by gentle pipetting.
Quantitation of viral RNA by slot blot hybridization
Viral RNA was quantitated using a slot blot hybridization
technique. See Supplementary Material for full details.
Quantitation of retroviral titer by flow cytometry based
expression analysis for EGFP
We developed a flow cytometry assay to rapidly measure
the titer of infectious viral particles (Fig. 1). This assay
takes advantage of the fluorescent properties of the EGFP
transgene. A total of 2 × 105 NIH 3T3 cells were trans-
duced with serial dilutions of supernatant. The transduc-
tion efficiency was measured by flow cytometry, and viral
titer was calculated at limiting dilution according to the fol-
lowing formula:
Titer (cfu/ml) = (2 × 105 target cells) × (% EGFP+ cells)/
volume of supernatant (ml).
Figure 1
Quantitation of viral titer. Murine fibroblast NIH 3T3 cells (2 × 105) were transduced with (a) 1000 µl, (b) 100 µl , or (c) 10 µl of unconcentrated
pRET2.EGFP supernatant. The percentage of enhanced green fluorescent protein (EGFP)-positive cells was measured by flow cytometry 
(% EGFP+ cells indicated in each panel). Titer was calculated using the volume of supernatant yielding <10% EGFP+ cells. In this example: 
Titer = 0.043 × (2 × 105 target cells) / 0.01 ml = 0.86 × 106 cfu/ml. For concentrated supernatant, smaller volumes were required to achieve
transduction efficiencies <10%.
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Transduction of primary human FLS
The FLS were plated in 6-well dishes at 2 × 105 cells/well.
FLS were cultured with viral supernatant plus protamine
sulfate (5 µg/ml) for 24 hours. Cells were analyzed for
transgene expression 72 hours after infection.
Results
Concentration of viral supernatant
To determine if viral titer influenced the transduction effi-
ciency of FLS, we optimized a superspeed centrifugation
protocol for concentration of viral supernatant. Prior studies
reported improved transduction of primary cells with retro-
virus concentrated by centrifugation at 6000 g for 16 hours
[9–11]. We systematically evaluated different centrifugation
parameters to minimize the time required for maximal con-
centration while preserving viral infectivity. A virally encoded
EGFP transgene [12–14] was used to monitor viral concen-
tration and infectious titer. We concentrated viral super-
natant 100-fold in as few as four hours by centrifugation at
20,000 g, with complete recovery of infectious viral parti-
cles. This data is presented in the Supplementary Material
(Supplementary Figs 1, 2, 3, and 4).
Retroviral transduction of primary human synoviocytes
Concentrated virus was tested for its ability to transduce
primary FLS. As shown in Figure 2 and Table 1, concen-
tration of viral supernatant increased FLS transduction.
We found that 14.2 ± 8.2% of FLS expressed EGFP fol-
lowing transduction with unconcentrated supernatant,
compared with 41.3 ± 14.7% for 10X concentrated
supernatant (P < 0.01, compared with unconcentrated
supernatant), and 47.3 ± 14.8% for 100X concentrated
supernatant (P < 0.01, compared with unconcentrated
supernatant).
To provide confirmation that improved transduction of FLS
was associated with an increase in the intracellular expres-
sion of a virally encoded transgene, FLS were transduced
with a vector encoding human COX-2 (pRET2.COX2). The
expression of COX-2 was measured by western blot on
whole cell lysates [6]. A substantial increase in net COX-2
expression was observed following transduction with both
10X and 100X concentrated viral supernatant (Fig. 3).
Discussion
We are characterizing molecular pathways involved in syn-
ovial pathophysiology by overexpression of biologically rel-
evant transgenes and dominant negative inhibitors in FLS.
The limited expansion potential of FLS, combined with the
low efficiency of existing methods, stimulated a systematic
examination of various transduction techniques to identify
a rapid and efficient method for stable genetic modifica-
tion of FLS. In this manuscript, we report a retroviral vector
system and transduction protocol with the capacity to
express a viral transgene in 50% or more of primary
human FLS after a single exposure to virus. We have sub-
sequently used this methodology to successfully express
a panel of transgenes in FLS (L Crofford and K McDon-
agh, unpublished observations). We believe this approach
will be of value to investigators addressing similar mecha-
nistic questions in FLS.
Previous studies exploring the use of recombinant MoMLV
vectors concluded that FLS were relatively resistant to
transduction [2–5], limiting enthusiasm for this approach.
The basis for this resistance was unclear, but could be
attributable to many factors including vector design, viral
titer, or biologic features inherent to FLS. Our experiments
differ from prior studies of retroviral gene transfer to FLS in
several important respects that may impact on the
observed results. First, our viral backbone is a modified
MoMLV vector that incorporates genetic elements (myelo-
proliferative sarcoma virus long-terminal repeats and B2
mutation) associated with resistance to transcriptional
silencing following proviral integration in primary cells
[7,8]. While we did not perform a detailed comparison of
EGFP expression in FLS using the modified and unmodi-
fied vector backbones, preliminary experiments suggested
that the modified vector was superior (J Yang, unpub-
lished observations). A similar, modified MoMLV vector
has been used to stably express EGFP in human marrow
stromal cells [15], another fibroblast-like primary cell type.
A second distinction is the use of EGFP as a transgene,
whereas prior studies relied on lacZ or beta-galactosi-
dase. The expression of EGFP is readily detectable in
living cells by fluorescence microscopy or flow cytometry,
and expression can be monitored serially over time in a
single culture. In contrast to staining for lacZ, which is
often complicated by background staining from endoge-
nous galactosidase activity, there is no significant back-
ground staining with EGFP. We do not know if analysis of
EGFP expression is more or less sensitive than analysis
for lacZ expression, although we believe it provides more
reproducible and quantitative data due to the absence of
background staining.
Using this vector system, we observed a low ex vivo trans-
duction efficiency (14.2 ± 8.2%) of FLS with unconcen-
trated supernatant (titer of 106 cfu/ml) that was roughly
comparable to prior reports. Centrifugal concentration of
viral supernatant by 10- to 100-fold significantly increased
the efficiency of viral transduction, with 50% or more of
FLS expressing EGFP in several independent experiments
using FLS lines from separate donors. Concentration of
supernatant to viral titers exceeding 107 cfu/ml appeared
to have the greatest quantitative impact on improving trans-
duction efficiency. Increasing viral titer to 108 cfu/ml
yielded an additional increase in transduction efficiency in
some, but not all experiments. This observation suggests
that factors in addition to viral titer may limit the maximum
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Table 1
Viral transduction of fibroblast-like synovial cells
Unconcentrated  10X Concentrated  100X Concentrated 
FLS Line Negative control supernatant supernatant supernatant
RA16 0.1 8.2 33.3 25.4
RA25 0.6 23.7 62.2 63.5
RA30 0.0 15.8 40.7 58.2
RA31 0.2 3.7 23.1 45.5
RA32 0.2 19.6 47.3 43.9
Mean ± SD 0.2 ± 0.2% 14.2 ± 8.2% 41.3 ± 14.7%* 47.3 ± 14.8%**
Fibroblast-like synovial cells (FLS) were transduced with pRET2.EGFP retroviral supernatant. The values represent the percentage of enhanced
green fluorescent protein-positive cells by flow cytometry. *P < 0.01 compared with unconcentrated supernatant; **P > 0.05 compared with 10X
supernatant.
Figure 2
Transduction of fibroblast-like synovial cells (FLS) with pRET2.EGFP. The FLS from patients with rheumatoid arthritis (RA) were transduced with
(a) (d) (g) unconcentrated, (b) (e) (h) 10X concentrated, or (c) (f) (i) 100X concentrated pRET2.EGFP supernatant. (a–c) The percentage of
EGFP-positive FLS was determined by flow cytometry. (d–f) Light and (g–i) fluorescence microscopy images of cultures following transduction are
shown. These results are representative of data using FLS isolated from 5 RA patients.
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conditions. Lentiviral vectors have the capacity to trans-
duce nonreplicating cells [16], and may represent an alter-
native to MoMLV-based vectors for some applications.
Conclusion
We report a retroviral vector system and transduction
methodology that achieve stable transgene expression in
primary human FLS with efficiencies of approximately
50%. These results establish the feasibility of using widely
available retroviral gene transfer techniques to study the
biologic impact of overexpression of specific regulatory
and inflammatory molecules in primary FLS.
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Supplementary material
Supplementary Introduction
Synovial cells play a central role in the pathophysiology of
inflammatory arthritis. Much of our understanding of this
biology has been derived from the study of primary fibrob-
last like synovial cells cultured from arthritic joints after
arthroscopic biopsy or surgery. Stable genetic modifica-
tion of primary synovial cells is an approach that may be
useful in defining the roles that specific signaling path-
ways or inflammatory mediators play in the joint destruc-
tion associated with rheumatoid arthritis. As our
understanding of this biology improves, investigators have
also proposed that gene transfer to primary synovial cells
could be developed as a therapeutic approach to the
treatment of patients with inflammatory arthritis [2,3].
Recombinant retroviral vectors are widely used in the labo-
ratory, and in experimental clinical applications, to intro-
duce new genetic material into the host genome in a
stable form. Retroviral packaging cells routinely yield viral
supernatants with titers in the range of 105 to 106 cfu/ml
or higher, and titers of up to 107 cfu/ml may be achieved
in some cases. Physical methods to concentrate viral
supernatants have been pursued with mixed results. Ultra-
centrifugation can be used to physically concentrate
MoMLV-based retroviral particles, but viral infectivity is
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Figure 3
Expression of cyclooxygenase-2 (COX-2) in transduced fibroblast-like
synovial cells (FLS). The FLS from patients with rheumatoid arthritis
were transduced with retrovirus. Lane 1: 100X concentrated
RET2.EGFP; lane 2: 100X concentrated RET2.COX2; lane 3: 10X
concentrated RET2.COX2; lane 4: unconcentrated RET2.COX2; lane
5: post-centrifugation supernatant RET2.COX2. Whole cell lysates
were analyzed for COX-2 by western blot (lane 6: purified COX-2
protein). The experiment was repeated using FLS lines from different
patients with similar results.
123 4 5 6
¬ COX-2impaired secondary to damage to the envelope protein.
Pseudotyped retroviruses containing the vesicular stomati-
tis virus G protein are more robust, and can be concen-
trated more than 100-fold by ultracentrifugation without
significant loss of viral infectivity. However, because of the
toxicity of the vesicular stomatitis virus G glycoprotein,
only transient methods of virus production have been
described [S1,S2]. Bowles et al. previously reported a
superspeed centrifugation technique for concentration of
recombinant retrovirus [9]. A MoMLV based recombinant
retrovirus was concentrated over 100-fold by centrifuga-
tion at 6000 g for 16 hours.
Supplementary Materials and methods
Cell culture
The murine fibroblast NIH 3T3 cell line (CCL 92) and the
amphotropic retroviral packaging cell line PA317 (CRL
9078) were obtained from the American Type Culture Col-
lection (Rockville, MD, USA ). The Phoenix-E ecotropic
packaging cell line was obtained from Dr Gary Nolan
(Stanford University, USA).
Isolation of amphotropic producer cells
A transinfection technique was used to rapidly establish a
polyclonal amphotropic producer line of moderate to high
titer. The pRET2.EGFP or pRET2.COX2 plasmids were
transfected into ecotropic Phoenix E packaging cells by
the calcium phosphate precipitation method, using the
ProFection kit (Promega, Madison, WI, USA). Retroviral
supernatant was collected 48 hours after transfection, fil-
tered through a 0.45 µM filter (Nalgene, Rochester, NY,
USA), supplemented with 5 µg/ml protamine sulfate
(Elkins-Sinn, Inc. Cherry Hill, NJ, USA), and incubated with
amphotropic PA317 packaging cells for 24 hours. The
transinfection procedure was repeated twice. Following
transinfection with ecotropic viral supernatant, 100% of
the PA317 cells were transduced with the pRET2.EGFP
vector, as determined by fluorescence microscopy. The
successful transinfection of pRET2.COX2 into PA317
was confirmed by G418 selection. These polyclonal popu-
lations of PA317 producer cells were used as the source
of viral supernatant for subsequent viral transduction and
concentration experiments. The presence of replication
competent retrovirus was excluded by PCR for viral enve-
lope coding sequence in genomic DNA isolated from
virally transduced NIH 3T3 target cells (primers: 5′-AAG-
GTGGTAAACCAGGGGGATC-3′ and 5′-TGAGCAGCT-
TCATGCCGCTATC-3′).
Quantitation of viral RNA by slot blot hybridization
A nylon transfer membrane (Micron Separations Inc.
Westborough, MA, USA) was soaked in 10X SSC for
10 min and inserted into a BRL convertible filtration mani-
fold system (BRL Life Technologies Inc. Gaithersburg,
MD, USA). Each well was washed twice with 200 µl of
10X SSC immediately before sample loading. Retroviral
supernatant samples were directly loaded onto the mem-
brane without further preparation. After application of the
sample to the membrane, the wells were washed three
times with 200 µl of 10X SSC. The membrane was cross-
linked with UV light (Stratalinker 1800, Stratagene, La
Jolla, CA, USA) and stored for analysis by hybridization.
An EGFP probe fragment (~800 base pairs) was pre-
pared by PCR and labeled with 32P-dCTP (Amersham Life
Science Inc., Arlington Heights, IL, USA) using a kit
(Prime-It RmT, Stratagene, La Jolla, CA, USA). The mem-
brane was prehybridized for 2 hours at 42oC in 10 ml of
hybridization buffer (final concentrations: 50% formamide,
5X Denhardt’s solution, 0.1% SDS, 5X SSPE, 150 µg/ml
denatured herring sperm DNA), and hybridized with the
denatured probe overnight in 5 ml of hybridization buffer at
42°C. The membrane was washed twice with 2X SSPE at
room temperature for 10 min, three times with 0.1X
SSPE/0.5% SDS at 55°C for 30 min, and twice with 0.1X
SSPE at room temperature for 10 min. The autoradi-
ograph was visualized by exposing the membrane to X-ray
film at –80°C with an intensifying screen.
Quantitation of retroviral titer by FACS based
expression analysis for EGFP
The NIH 3T3 cells were plated in 6-well tissue culture
dishes at a density of 105 cells per well. The following day,
the medium was replaced with 2 ml of fresh medium con-
taining a defined volume of viral supernatant, supple-
mented with protamine sulfate (5 µg/ml). After exposure to
viral supernatant for 24 hours, the medium was replaced
with fresh, virus-free medium and the cells were cultured
for an additional 48 hours. At the conclusion of the experi-
ment, the cells were trypsinized and analyzed by flow
cytometry on an EPICS XL (excited by 488 nm light, using
a 530 ± 15 nm bandpass filter to detect the signal on
FL1) to determine the percentage of cells expressing
EGFP. In all cases, serial dilutions of viral supernatant
were tested.
Supplementary Results
Optimization of the centrifugation protocol
Duration of centrifugation
Supernatant collected from the RET2.EGFP producer
cells was centrifuged at 6000 g for time periods varying
between 1 and 20 hours. After centrifugation, the super-
natant was collected and saved for quantitation of residual
viral particles. The viral pellets were resuspended in a thir-
tieth of the original volume of the supernatant. As mea-
sured on NIH 3T3 cells by flow cytometry, viral titer
increased 14-fold after four hours of centrifugation, and
appeared to plateau after 12 hours of centrifugation at
1.34 × 107 cfu/ml (Supplementary Fig. 1). There was a
proportional decline in the viral titer of the post-centrifuga-
tion supernatant. Even following concentration for as long
as 20 hours, the infectivity of the recombinant virus was
preserved.
Arthritis Research    Vol 4 No 3 Yang et al.To confirm the viral titer derived by expression analysis, we
performed slot blot hybridization analysis on viral RNA in
the postcentrifugation supernatant and the resuspended
viral pellet (Supplementary Fig. 2). Following centrifuga-
tion at 6000 g for four hours, most retroviral RNA was
concentrated in the viral pellet. Almost no retroviral RNA
remained in the postcentrifugation supernatant after cen-
trifugation for 12 hours.
Relative centrifugal force
To further optimize the concentration procedure, we exam-
ined a range of relative centrifugal force (RCF). The time
of centrifugation was fixed at four hours and the RCF was
varied in a range from 6000 to 30,000 g. Following cen-
trifugation, the viral pellet was resuspended in a hundredth
of the original volume. Viral titer was quantitated by
expression studies in NIH 3T3 cells (Supplementary
Fig. 3) and slot blot hybridization analysis (Supplementary
Fig. 4). We observed a progressive rise in viral titer as
RCF was increased from 6000 to 20,000 g. At a RCF of
20,000 g, the titer of the resuspended pellet reached a
plateau value of 1.3 × 108 cfu/ml. Further concentration of
viral particles was not achieved by increasing RCF above
20,000 g. Viral particles were not detectable by expres-
sion assay or by slot blot hybridization analysis in the post-
centrifugation supernatant at an RCF of 20,000 g or
higher. The expression data also suggested that centrifu-
gation at a RCF as high as 30,000 g for four hours did not
affect viability of the recombinant retrovirus.
Supplementary Discussion
The FLS are the principal cell type of sublining synovial
tissue. Proliferation of FLS is observed in RA, a debilitating
condition that affects as many as 1–2% of adult individu-
als worldwide. Primary FLS cultures can be established
following arthroscopic biopsy or surgical resection of syn-
ovium from the joint. Protease digested synovial tissues
placed in culture rapidly yield fibroblast-like cells. After
three passages, these primary cultures are depleted of
macrophage-like type A synoviocytes [S3]. Doubling time
is stable between the third and the tenth passages, but
marked reduction in proliferation rate occurs in later
passage cells [S4].
Retroviral mediated gene transfer is a commonly used
technique to stably introduce genes into primary cells. The
titer of retroviral supernatant is one of several factors that
influence transduction efficiency. A variety of strategies
have been employed to physically concentrate retroviral
particles in an attempt to further increase viral titer and
improve the efficiency of target cell transduction. Centrifu-
gation of retroviral supernatant is a potentially attractive
approach to viral concentration because of the wide avail-
ability of centrifuge equipment, the simplicity of the tech-
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Supplementary Figure 2
Quantitation of viral RNA by slot blot hybridization analysis after
concentration of virus by centrifugation at 6000 g. Viral supernatant was
centrifuged at 6000 g for the time periods indicated. The viral pellet was
resuspended in a thirtieth of the original volume. The indicated volumes
of (a) unconcentrated supernatant, (b) the resuspended viral pellet, and
(c) the post-centrifugation supernatant were loaded onto a nylon
membrane in a 48-well slot blot format, hybridized with an enhanced
green fluorescent protein probe, and exposed to film. Experiments were
repeated three times with similar results.
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Supplementary Figure 1
Quantitation of functional viral titer following time course optimization.
Viral supernatant was centrifuged at 6000 g for the time periods
indicated. The viral pellet was resuspended in a thirtieth of the original
volume. The viral titer of the post-centrifugation supernatant (solid
bars) and the resuspended viral pellet (open bars) were measured on
NIH 3T3 cells by the FACS-based limiting dilution expression assay.
Data are representative of three similar experiments.
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Pelletnique, and the theoretical potential for rapid processing of
large sample volumes.
Concentrated recombinant retrovirus, generated by super-
speed centrifugation of retroviral supernatant, has been
used to improve the transduction efficiency of primary
cells, including hepatocytes [9] and endothelial cells [11].
In these prior reports, concentration was accomplished by
centrifugation for 16 hours at a RCF of 6000 g. We used
a recombinant retrovirus encoding the green fluorescent
protein to optimize a protocol to rapidly and efficiently con-
centrate retrovirus by superspeed centrifugation. Our
studies indicate that the time necessary to recover essen-
tially all viral particles can be reduced to four hours by
increasing the RCF to 20,000 g. The protocol does not
appear to adversely affect the infectivity of the viral prepa-
ration, as the functional viral titer on NIH 3T3 cells closely
matched the titer that was predicted by the degree of con-
centration. Although it has been reported that centrifuga-
tion may result in concurrent concentration of
noninfectious viral particles or inhibitors of viral transduc-
tion [S5], we have been able to substantially increase the
transduction efficiency of primary FLS using concentrated
viral supernatant produced by our protocol. This optimized
technique may be useful in generating high titer retroviral
supernatants from production lots of relatively modest
titer. We anticipate that this method will be effective in
concentrating other pseudotyped MoMLV vectors and
lentivirus based vectors, though additional testing will be
required to evaluate its suitability for each vector system.
While our studies were not initiated with the objective of
developing a therapeutic protocol, these results may also
have implications for clinical studies. The ex vivo genetic
modification of FLS has been proposed as a potential
approach to the treatment of arthritis [S6,S7]. In these
studies, FLS are cultured from synovial tissue obtained by
synovectomy, transduced with retroviral supernatant ex
vivo, and injected into another joint of the same individual.
Approval for these clinical studies was based on ex vivo
transduction data in preclinical animal models [S8,S9].
Essentially, all data on transduction efficiency of FLS was
derived using retroviral vectors that express lacZ or beta-
galactosidase. Although most authors have obtained ex
vivo transduction efficiencies of cultured FLS in the range
of 1–5%, some have reported transduction efficiencies up
to 20%. Preactivation of FLS with tumor necrosis factor α,
however, may increase transduction efficiency levels to
over 30% [S8].
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Supplementary Figure 3
Quantitation of functional viral titer following optimization of relative
centrifugal force. Viral supernatant was centrifuged for four hours at
the indicated relative centrifugal force. The viral pellet was
resuspended in a hundredth of the original volume. The functional viral
titer of the post-centrifugation supernatant (solid bars) and the
resuspended viral pellet (open bars) were measured on NIH 3T3 cells
by the FACS-based limiting dilution expression assay. Data are
representative of three similar experiments.
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Supplementary Figure 4
Quantitation of viral RNA by slot blot hybridization analysis after
concentration of virus by centrifugation for four hours. Viral supernatant
was centrifuged for four hours at the indicated relative centrifugal force
(RCF). The viral pellet was resuspended in a hundredth of the original
volume. The indicated volumes of (a) unconcentrated supernatant, (b)
the resuspended viral pellet, and (c) the post-centrifugation
supernatant were loaded onto a nylon membrane in a 48-well slot blot
format, hybridized with an enhanced green fluorescent protein probe,
and exposed to film. Experiments were repeated three times with
similar results.
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